Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 30 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 5 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced a licensing agreement with Sun Pharma for co-marketing Desidustat, an innovative oral treatment for anemia associated with Chronic Kidney Disease in India. Under this agreement, Sun Pharma will market the drug as RYTSTAT while Zydus will continue to market it as Oxemia™. Zydus will receive upfront licensing income and milestone payments based on specific achievements.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 30, 2023, titled "Zydus and Sun Pharma sign licensing agreement for co-marketing of Desidustat, a critical treatment for Chronic Kidney Disease patients in India".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases